SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 87 of 94
Word Count: 1464
Character Count: 9952

Document Content:

in selling, general administration expenses in 2024. See Note 7. June 2024, the Company issued 132,674 shares of common stock to former Series A-1 preferred stock shareholders that were owed shares due to a miscalculation of shares issued as part of the re-capitalization of the Company on February 2, 2023. There was no additional cash received by the Company for the issuance of these shares. August 2024, the Company amended its Certificate of Incorporation to increase the number of authorized shares of common stock to 25,000,000 and preferred stock to 12,500,000 shares of which 6,000,000 were designated Series A and 6,500,000 were designated blank check preferred stock. August 2024, the Company adopted the 2024 Equity Incentive Plan (the “2024 Plan”), which provides for the granting of incentive stock options, nonstatutory stock options and restricted stock awards to employees, directors and consultants of the Company and its affiliates. See Note 10.

September 2024, the Company issued 231,000 shares of restricted common stock to certain officers, directors and consultants of the Company.
The restricted stock was valued at $0.80 per share based on an independent 409A valuation received from a global financial advisory firm
specializing in corporate finance and business enterprise valuations. As 134,745 shares vested by December 31, 2024, the Company recorded
$107,796 in selling, general administration expenses in 2024. The remaining 96,255 shares vested in 2025. See Note 7.

October 2024, the Company filed Certificate of Designations of Series A-1 Preferred Stock providing for the authorization of 1,200,000
shares of Series A-1 Preferred Stock from the authorized but undesignated Blank Check Preferred Stock.

BIOVENTRIX,
INC.

Notes
to Consolidated Financial Statements

December
31, 2025 and 2024

a result of the above transactions, total shares as of December 31, 2024, were as follows:

Class
of Security Shares
Authorized Shares
Outstanding Shares
Available

Common 23,500,000 5,616,390 17,883,610

Common Stock Options 1,500,000 - 1,500,000

Series A Preferred 6,000,000 1,565,000 4,435,000

Series A-1 Preferred 1,200,000 - 1,200,000

Blank
Check Preferred 5,300,000 - 5,300,000

December

January 2025, the Company granted 413,000 incentive stock options to officers under the Company’s equity incentive plan. The options
have an exercise price equal to the fair value of the Company’s common stock on the grant date. Of the total options granted, 103,250
vested in 2025 and the remaining 309,750 vest in equal monthly installments through December 2028, subject to continued service. The
options are equity-classified awards.

The
weighted-average grant-date fair value of the options was $0.39 per share, resulting in an aggregate grant-date fair value of $159,808.
The fair value was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility
of 50%, expected term of 6 years, risk-free interest rate of 4.62%, and an expected dividend yield of 0%.

The
Company recognized $39,952 of stock-based compensation expense related to these options during the year ended December 31, 2025, which
was recorded in selling, general and administrative expenses. As of December 31, 2025, total unrecognized compensation cost related to
unvested stock options was $119,856, which is expected to be recognized over a weighted-average remaining vesting period of 3.0
years. See Note 7.

February 2025, the Company granted 85,000 incentive stock options to employees under the Company’s equity incentive plan. The options
have an exercise price equal to the fair value of the Company’s common stock on the grant date. Of the total options granted, 19,479
vested in 2025 and the remaining 65,521 vest in equal monthly installments through January 2029, subject to continued service. The options
are equity-classified awards.

The
weighted-average grant-date fair value of the options was $0.39 per share, resulting in an aggregate grant-date fair value of $32,776.
The fair value was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility
of 50%, expected term of 6 years, risk-free interest rate of 4.52%, and an expected dividend yield of 0%.

BIOVENTRIX,
INC.

Notes
to Consolidated Financial Statements

December
31, 2025 and 2024

The
Company recognized $7,511 of stock-based compensation expense related to these options during the year ended December 31, 2025, which
was recorded in selling, general and administrative expenses. As of December 31, 2025, total unrecognized compensation cost related to
unvested stock options was $25,265, which is expected to be recognized over a weighted-average remaining vesting period of 3.1
years.

April 2025, the Company filed Certificate of First Amendment of Certificate of Designations of Series A-1 Preferred Stock increasing
the amount of authorized shares designated as Series A-1 Preferred Stock from 1,200,000 shares to 3,000,000 shares from the Company’s
authorized Blank Check Preferred Stock.

May 2025, the remaining 96,225 of restricted common stock awards issued in September 2024 became fully vested.

June 2025, the Company granted 30,000 incentive stock options to employees under the Company’s equity incentive plan. The options
have an exercise price equal to the fair value of the Company’s common stock on the grant date. Of the total options granted, 3,750
vested in 2025 and the remaining 26,250 vest in equal monthly installments through May 2029, subject to continued service. The options
are equity-classified awards.

The
weighted-average grant-date fair value of the options was $0.38 per share, resulting in an aggregate grant-date fair value of $11,496.
The fair value was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility
of 50%, expected term of 6 years, risk-free interest rate of 4.34%, and an expected dividend yield of 0%.

The
Company recognized $1,437 of stock-based compensation expense related to these options during the year ended December 31, 2025, which
was recorded in selling, general and administrative expenses. As of December 31, 2025, total unrecognized compensation cost related to
unvested stock options was $10,059, which is expected to be recognized over a weighted-average remaining vesting period of 3.5
years.

August 2025, the Company filed Certificate of Second Amendment of Certificate of Designations of Series A-1 Preferred Stock increasing
the amount of authorized shares designated as Series A-1 Preferred Stock from 3,500,000 shares to 5,500,000 shares the Company’s
authorized Blank Check Preferred Stock.

October 2025, the Company granted 177,500 incentive stock options to officers and employees under the Company’s equity incentive
plan. The options have an exercise price equal to the fair value of the Company’s common stock on the grant date. Of the total
options granted, 11,094 vested in 2025 and the remaining 166,406 vest in equal monthly installments through September 2029, subject to
continued service. The options are equity-classified awards. See Note 7.

BIOVENTRIX,
INC.

Notes
to Consolidated Financial Statements

December
31, 2025 and 2024

The
weighted-average grant-date fair value of the options was $0.60 per share, resulting in an aggregate grant-date fair value of $105,561.
The fair value was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility
of 50%, expected term of 6 years, risk-free interest rate of 4.12%, and an expected dividend yield of 0%.

The
Company recognized $6,604 of stock-based compensation expense related to these options during the year ended December 31, 2025, which
was recorded in selling, general and administrative expenses. As of December 31, 2025, total unrecognized compensation cost related to
unvested stock options was $99,057, which is expected to be recognized over a weighted-average remaining vesting period of 3.8
years.

October 2025, the Company granted 245,000 non-qualified stock options to members of the board of directors, consultants and an officer
under the Company’s equity incentive plan. The options have an exercise price equal to the fair value of the Company’s common
stock on the grant date. Of the total options granted, 15,313 vested in 2025 and the remaining 229,687 vest in equal monthly installments
through September 2029, subject to continued service. The options are equity-classified awards. See Note 7.

The
weighted-average grant-date fair value of the options was $0.60 per share, resulting in an aggregate grant-date fair value of $145,842.
The fair value was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility
of 50%, expected term of 6 years, risk-free interest rate of 4.12%, and an expected dividend yield of 0%.

The
Company recognized $9,115 of stock-based compensation expense related to these options during the year ended December 31, 2025, which
was recorded in selling, general and administrative expenses. As of December 31, 2025, total unrecognized compensation cost related to
unvested stock options was $136,727, which is expected to be recognized over a weighted-average remaining vesting period of 3.8
years.

a result of the above transactions, total shares as of December 31, 2025, were as follows:

Class
of Security Shares
Authorized Shares
Outstanding Shares
Available

Common 23,500,000 5,712,645 17,787,355

Common Stock Options 1,500,000 950,500 549,500

Series A Preferred 6,000,000 1,565,000 4,435,000

Series A-1 Preferred 5,500,000 - 5,500,000

Blank
Check Preferred 1,000,000 - 1,000,000

December

BIOVENTRIX,
INC.

Notes
to Consolidated Financial Statements

December
31, 2025 and 2024

Rights
and Preferences of Preferred Shareholders